Tango Therapeutics, Inc.
TNGX
株式のランク
#4551
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
株価
$27.18
最終同期: 2026-07-31
時価総額
$3.38B
変化（1日）
-1.41%
変化（1年）
202.34%
国
US
取引 Tango Therapeutics, Inc. (TNGX)
カテゴリー
Healthcare
Tango Therapeutics, Inc.（TNGX）の利益
Jun 2026 時点の利益 TTM: $-123.78M
Tango Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $-123.78M です。2023 年には $-101.61M の利益を上げ、これは 2022 年の利益 $-108.12M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Tango Therapeutics, Inc. の利益の推移（2019 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-123.78M | -4.85% |
| 2024 | $-130.09M | 28.03% |
| 2023 | $-101.61M | -6.02% |
| 2022 | $-108.12M | 86.60% |
| 2021 | $-57.94M | 11.49% |
| 2020 | $-51.97M | 268.73% |
| 2019 | $-14.10M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -4,361.41% |
US
|
|
| $-3.09B | 2,393.88% |
US
|
|
| $-4.02B | 3,144.55% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,675.86% |
NL
|
